ES2395121T3 - Métodos para el diagnóstico del cáncer en base a genes OBCAM y NTM - Google Patents

Métodos para el diagnóstico del cáncer en base a genes OBCAM y NTM Download PDF

Info

Publication number: ES2395121T3
Authority: ES; Spain
Prior art keywords: obcam; ntm; nucleic acid; polypeptide; cancer
Prior art date: 2001-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES02743382T

Other languages

English (en)

Spanish (es)

Inventor

Grant Clark Sellar

Hani Gabra

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cancer Research Technology Ltd

Original Assignee

Cancer Research Technology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-27

Filing date

2002-06-20

Publication date

2013-02-08

2002-06-20 Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd

2002-06-20 Priority claimed from PCT/GB2002/002928 external-priority patent/WO2003002765A2/en

2013-02-08 Application granted granted Critical

2013-02-08 Publication of ES2395121T3 publication Critical patent/ES2395121T3/es

2022-06-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 190
238000000034 method Methods 0.000 title claims abstract description 166
201000011510 cancer Diseases 0.000 title claims abstract description 115
101710096745 Opioid-binding protein/cell adhesion molecule Proteins 0.000 title claims abstract description 81
102100026742 Opioid-binding protein/cell adhesion molecule Human genes 0.000 title claims abstract description 75
101000596892 Homo sapiens Neurotrimin Proteins 0.000 title claims abstract description 46
238000003745 diagnosis Methods 0.000 title claims description 12
102100035107 Neurotrimin Human genes 0.000 claims abstract description 265
150000007523 nucleic acids Chemical class 0.000 claims abstract description 175
102000039446 nucleic acids Human genes 0.000 claims abstract description 174
108020004707 nucleic acids Proteins 0.000 claims abstract description 174
101150104007 NTM gene Proteins 0.000 claims abstract description 100
239000002299 complementary DNA Substances 0.000 claims abstract description 98
108700028369 Alleles Proteins 0.000 claims abstract description 94
108090000623 proteins and genes Proteins 0.000 claims description 174
108090000765 processed proteins & peptides Proteins 0.000 claims description 136
102000004196 processed proteins & peptides Human genes 0.000 claims description 134
108020004414 DNA Proteins 0.000 claims description 130
229920001184 polypeptide Polymers 0.000 claims description 129
239000000523 sample Substances 0.000 claims description 117
239000002773 nucleotide Substances 0.000 claims description 87
125000003729 nucleotide group Chemical group 0.000 claims description 87
230000011987 methylation Effects 0.000 claims description 85
238000007069 methylation reaction Methods 0.000 claims description 85
206010061535 Ovarian neoplasm Diseases 0.000 claims description 82
206010033128 Ovarian cancer Diseases 0.000 claims description 60
230000000694 effects Effects 0.000 claims description 44
230000002611 ovarian Effects 0.000 claims description 35
238000001514 detection method Methods 0.000 claims description 29
108091029523 CpG island Proteins 0.000 claims description 28
238000011282 treatment Methods 0.000 claims description 28
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 26
239000013068 control sample Substances 0.000 claims description 26
102000004169 proteins and genes Human genes 0.000 claims description 26
230000003321 amplification Effects 0.000 claims description 25
238000003199 nucleic acid amplification method Methods 0.000 claims description 25
206010009944 Colon cancer Diseases 0.000 claims description 24
239000013610 patient sample Substances 0.000 claims description 23
108020004999 messenger RNA Proteins 0.000 claims description 21
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 19
238000006243 chemical reaction Methods 0.000 claims description 18
201000010099 disease Diseases 0.000 claims description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
238000003556 assay Methods 0.000 claims description 16
150000001413 amino acids Chemical group 0.000 claims description 14
210000004369 blood Anatomy 0.000 claims description 14
239000008280 blood Substances 0.000 claims description 14
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 13
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 13
230000004927 fusion Effects 0.000 claims description 12
239000004475 Arginine Substances 0.000 claims description 11
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
210000001072 colon Anatomy 0.000 claims description 11
229940104302 cytosine Drugs 0.000 claims description 8
208000029742 colonic neoplasm Diseases 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000003153 chemical reaction reagent Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000002349 favourable effect Effects 0.000 claims description 3
239000002253 acid Substances 0.000 abstract description 3
230000002378 acidificating effect Effects 0.000 abstract 1
108010042350 neurotrimin Proteins 0.000 description 228
210000004027 cell Anatomy 0.000 description 151
238000003752 polymerase chain reaction Methods 0.000 description 84
230000035772 mutation Effects 0.000 description 82
239000013615 primer Substances 0.000 description 58
241000282414 Homo sapiens Species 0.000 description 55
230000014509 gene expression Effects 0.000 description 50
239000000047 product Substances 0.000 description 50
210000001519 tissue Anatomy 0.000 description 46
239000013598 vector Substances 0.000 description 41
210000001672 ovary Anatomy 0.000 description 29
210000000349 chromosome Anatomy 0.000 description 21
239000012634 fragment Substances 0.000 description 21
238000009396 hybridization Methods 0.000 description 20
230000014616 translation Effects 0.000 description 20
230000006870 function Effects 0.000 description 18
238000003757 reverse transcription PCR Methods 0.000 description 18
238000001890 transfection Methods 0.000 description 17
108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 16
238000004458 analytical method Methods 0.000 description 16
239000003550 marker Substances 0.000 description 16
238000012163 sequencing technique Methods 0.000 description 16
108700024394 Exon Proteins 0.000 description 15
230000002779 inactivation Effects 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 14
108090000790 Enzymes Proteins 0.000 description 14
230000000692 anti-sense effect Effects 0.000 description 14
210000004436 artificial bacterial chromosome Anatomy 0.000 description 14
230000037431 insertion Effects 0.000 description 14
238000003780 insertion Methods 0.000 description 14
108091008146 restriction endonucleases Proteins 0.000 description 14
230000027455 binding Effects 0.000 description 13
230000037430 deletion Effects 0.000 description 13
238000012217 deletion Methods 0.000 description 13
238000001415 gene therapy Methods 0.000 description 13
101000982440 Homo sapiens Opioid-binding protein/cell adhesion molecule Proteins 0.000 description 12
108010029485 Protein Isoforms Proteins 0.000 description 12
102000001708 Protein Isoforms Human genes 0.000 description 12
210000000981 epithelium Anatomy 0.000 description 12
238000012546 transfer Methods 0.000 description 12
101000693985 Homo sapiens Twinkle mtDNA helicase Proteins 0.000 description 11
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 11
102100027193 Twinkle mtDNA helicase Human genes 0.000 description 11
239000013612 plasmid Substances 0.000 description 11
238000013519 translation Methods 0.000 description 11
108091026890 Coding region Proteins 0.000 description 10
108091092195 Intron Proteins 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
125000003275 alpha amino acid group Chemical group 0.000 description 10
210000002950 fibroblast Anatomy 0.000 description 10
238000002105 Southern blotting Methods 0.000 description 9
230000008859 change Effects 0.000 description 9
102000040430 polynucleotide Human genes 0.000 description 9
108091033319 polynucleotide Proteins 0.000 description 9
239000002157 polynucleotide Substances 0.000 description 9
101100517375 Homo sapiens NTM gene Proteins 0.000 description 8
108091092878 Microsatellite Proteins 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
210000000481 breast Anatomy 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
238000007912 intraperitoneal administration Methods 0.000 description 8
239000012528 membrane Substances 0.000 description 8
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
238000012360 testing method Methods 0.000 description 8
239000001226 triphosphate Substances 0.000 description 8
235000011178 triphosphate Nutrition 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
230000012010 growth Effects 0.000 description 7
102000052815 human OPCML Human genes 0.000 description 7
230000003211 malignant effect Effects 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 6
206010069754 Acquired gene mutation Diseases 0.000 description 6
102000007469 Actins Human genes 0.000 description 6
108010085238 Actins Proteins 0.000 description 6
206010006187 Breast cancer Diseases 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
108060003951 Immunoglobulin Proteins 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
230000002776 aggregation Effects 0.000 description 6
238000004220 aggregation Methods 0.000 description 6
230000004075 alteration Effects 0.000 description 6
229960002756 azacitidine Drugs 0.000 description 6
230000029087 digestion Effects 0.000 description 6
102000018358 immunoglobulin Human genes 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000012188 paraffin wax Substances 0.000 description 6
230000037439 somatic mutation Effects 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
239000004677 Nylon Substances 0.000 description 5
108020005187 Oligonucleotide Probes Proteins 0.000 description 5
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 5
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 5
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 5
108700025716 Tumor Suppressor Genes Proteins 0.000 description 5
102000044209 Tumor Suppressor Genes Human genes 0.000 description 5
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 5
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 5
108010084455 Zeocin Proteins 0.000 description 5
231100000504 carcinogenesis Toxicity 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
239000003446 ligand Substances 0.000 description 5
239000002502 liposome Substances 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
238000005259 measurement Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
229920001778 nylon Polymers 0.000 description 5
239000002751 oligonucleotide probe Substances 0.000 description 5
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 5
238000004393 prognosis Methods 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
208000003200 Adenoma Diseases 0.000 description 4
101150072950 BRCA1 gene Proteins 0.000 description 4
208000005623 Carcinogenesis Diseases 0.000 description 4
230000007067 DNA methylation Effects 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
102000039967 IgLON family Human genes 0.000 description 4
108091069107 IgLON family Proteins 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
108020004711 Nucleic Acid Probes Proteins 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
208000009956 adenocarcinoma Diseases 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000036952 cancer formation Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002509 fluorescent in situ hybridization Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000002853 nucleic acid probe Substances 0.000 description 4
239000002777 nucleoside Substances 0.000 description 4
-1 nucleoside triphosphate Chemical class 0.000 description 4
238000011580 nude mouse model Methods 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
229910052697 platinum Inorganic materials 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
230000000392 somatic effect Effects 0.000 description 4
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 3
FICVQGAXQTVNNK-JHYUDYDFSA-N 4-amino-1-[(2r,4s,5s)-4-hydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](NO)[C@@H](O)C1 FICVQGAXQTVNNK-JHYUDYDFSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
101150008921 Brca2 gene Proteins 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
229930193140 Neomycin Natural products 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
238000010222 PCR analysis Methods 0.000 description 3
238000002944 PCR assay Methods 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000000137 annealing Methods 0.000 description 3
210000003050 axon Anatomy 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
238000007622 bioinformatic analysis Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000013599 cloning vector Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000017858 demethylation Effects 0.000 description 3
238000010520 demethylation reaction Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
229960005542 ethidium bromide Drugs 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000013507 mapping Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229960004927 neomycin Drugs 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
230000037443 ovarian carcinogenesis Effects 0.000 description 3
231100001249 ovarian carcinogenesis Toxicity 0.000 description 3
210000003200 peritoneal cavity Anatomy 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
102000054765 polymorphisms of proteins Human genes 0.000 description 3
230000002028 premature Effects 0.000 description 3
238000011002 quantification Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
101100217475 Arabidopsis thaliana ACA1 gene Proteins 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
102000036365 BRCA1 Human genes 0.000 description 2
108700020463 BRCA1 Proteins 0.000 description 2
108700040618 BRCA1 Genes Proteins 0.000 description 2
108700010154 BRCA2 Genes Proteins 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
241000701533 Escherichia virus T4 Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000683591 Homo sapiens Ras-responsive element-binding protein 1 Proteins 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
101710187339 Neuronal growth regulator 1 Proteins 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
206010061328 Ovarian epithelial cancer Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
208000006994 Precancerous Conditions Diseases 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
101100533932 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SPA2 gene Proteins 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
238000001369 bisulfite sequencing Methods 0.000 description 2
238000009534 blood test Methods 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
210000002230 centromere Anatomy 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
238000000975 co-precipitation Methods 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
230000009615 deamination Effects 0.000 description 2
238000006481 deamination reaction Methods 0.000 description 2
238000003936 denaturing gel electrophoresis Methods 0.000 description 2
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000001163 endosome Anatomy 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000004545 gene duplication Effects 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000002357 laparoscopic surgery Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
238000007726 management method Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
230000000869 mutational effect Effects 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
208000015124 ovarian disease Diseases 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
238000010186 staining Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 description 1
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
102000052609 BRCA2 Human genes 0.000 description 1
108700020462 BRCA2 Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
206010060999 Benign neoplasm Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
102000014837 CACNA1G Human genes 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
108091060290 Chromatid Proteins 0.000 description 1
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
230000008836 DNA modification Effects 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
208000014061 Extranodal Extension Diseases 0.000 description 1
208000009849 Female Genital Neoplasms Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000000321 Gardner Syndrome Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
208000016177 Genetic intestinal polyposis Diseases 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
101150009006 HIS3 gene Proteins 0.000 description 1
208000033640 Hereditary breast cancer Diseases 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000002979 Influenza in Birds Diseases 0.000 description 1
108010014691 Lithostathine Proteins 0.000 description 1
102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
102100022223 Neuronal growth regulator 1 Human genes 0.000 description 1
101710149086 Nuclease S1 Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
101100463348 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEA2 gene Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
239000012163 TRI reagent Substances 0.000 description 1
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000011292 agonist therapy Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
238000003491 array Methods 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
206010064097 avian influenza Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000004641 brain development Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
108010041758 cleavase Proteins 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000002052 colonoscopy Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
208000017338 epidermoid cysts Diseases 0.000 description 1
230000007608 epigenetic mechanism Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001036 exonucleolytic effect Effects 0.000 description 1
208000014804 familial ovarian cancer Diseases 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
208000025581 hereditary breast carcinoma Diseases 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000013275 image-guided biopsy Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
230000009247 menarche Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000007855 methylation-specific PCR Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
208000022499 mismatch repair cancer syndrome Diseases 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
101150075391 mtnN gene Proteins 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
108700025694 p53 Genes Proteins 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
206010034260 pelvic mass Diseases 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
238000000053 physical method Methods 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000037048 polymerization activity Effects 0.000 description 1
208000015768 polyposis Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000004853 protein function Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
208000011581 secondary neoplasm Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
238000005829 trimerization reaction Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

ES02743382T 2001-06-27 2002-06-20 Métodos para el diagnóstico del cáncer en base a genes OBCAM y NTM Expired - Lifetime ES2395121T3 (es)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GB0115673A GB0115673D0 (en)	2001-06-27	2001-06-27	Cancer
GB0115673		2001-06-27
US30513701P	2001-07-16	2001-07-16
US305137P		2001-07-16
US33079201P	2001-10-31	2001-10-31
US330792P		2001-10-31
PCT/GB2002/002928 WO2003002765A2 (en)	2001-06-27	2002-06-20	Methods for the diagnosis of cancer based on the obcam and ntm genes

Publications (1)

Publication Number	Publication Date
ES2395121T3 true ES2395121T3 (es)	2013-02-08

Family

ID=9917428

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES02743382T Expired - Lifetime ES2395121T3 (es)	2001-06-27	2002-06-20	Métodos para el diagnóstico del cáncer en base a genes OBCAM y NTM

Country Status (3)

Country	Link
AT (1)	ATE541049T1 (de)
ES (1)	ES2395121T3 (de)
GB (1)	GB0115673D0 (de)

2001
- 2001-06-27 GB GB0115673A patent/GB0115673D0/en not_active Ceased
2002
- 2002-06-20 ES ES02743382T patent/ES2395121T3/es not_active Expired - Lifetime
- 2002-06-20 AT AT02743382T patent/ATE541049T1/de active

Also Published As

Publication number	Publication date
GB0115673D0 (en)	2001-08-22
ATE541049T1 (de)	2012-01-15

Publication	Publication Date	Title
EP0705903B2 (de)	2009-08-12	Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
Dallol et al.	2002	SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers
US7432050B2 (en)	2008-10-07	Methods and compositions for detecting colon cancers
US6841350B2 (en)	2005-01-11	Methods of diagnosing prostate cancer through the detection of the presence or absence of Pax 2 mRNA
US20020098530A1 (en)	2002-07-25	Tumor suppressor gene
US20120207755A1 (en)	2012-08-16	Cancer
US20070218480A1 (en)	2007-09-20	Detection and diagnosis of smoking related cancers
AU2003295986A1 (en)	2004-06-18	Methods for identifying risk of breast cancer and treatments thereof
US20110059899A1 (en)	2011-03-10	Kruppel-like factor 6 (KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein
Presneau et al.	2003	The quest for a tumor suppressor gene phenotype
US10344333B2 (en)	2019-07-09	Methods for diagnosing a predisposition to develop cancer
ES2395121T3 (es)	2013-02-08	Métodos para el diagnóstico del cáncer en base a genes OBCAM y NTM
WO1999020168A2 (en)	1999-04-29	Germline mutations in the e-cadherin gene and method for detecting predisposition to cancer
EP1394268A1 (de)	2004-03-03	HNF1alpha als Tumor-Suppressor Gen und diagnostische sowie therapeutische Verwendungen davon
US20030087243A1 (en)	2003-05-08	Diagnosis, prognosis and treatment of cancer related to the Barx2 gene
WO2002012894A9 (en)	2003-04-03	Kruppel-like factor 6 (klf6), a tumorsuppressor protein, and dia gnostics, therapeutics, and screening based on this protein
WO2011124725A1 (en)	2011-10-13	Rad51c as a human cancer susceptibility gene
US6929910B2 (en)	2005-08-16	Diagnostic and therapeutic methods using the H37 tumor suppressor gene
WO2000037677A1 (en)	2000-06-29	Cancer related to human chromosome 16q tumor suppressor gene
Dolan	1999	Tumour Suppressor Genes As Markers of Neoplastic Progression in Barrett's Oesophagus
Sard et al.	1997	544 Abnormal structure, transcription and expression of the FHIT gene in lung cancer cell lines
Rökman	2004	In Search of High-penetrant Hereditary Prostate Cancer Susceptibility Genes in Finland
Liang	1997	United States Patent te
WO2005045062A2 (en)	2005-05-19	Gene expression and polymorphisms associated with lung cancer